Akebia Ther (AKBA) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $0.91 (+1.49%), Market cap $0.27B, 52-week low–high $1.01 ~ $4.01.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acut
Financial statements, price targets, institutional (13F) holdings and related news for Akebia Ther are updated in real time on BlackAll Trade.
Akebia Ther trades at $0.91 (+1.49%). Real-time quotes and charts are available on BlackAll Trade.
Akebia Ther has a market cap of about $0.27B.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadad